Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 18/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | GLS2 | Q9UI32 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | MPEG1 | Q2M385 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021982 | 0.98 | ACHE (0.40) | ACHEBACE1ALOX5PTGS2GLS2 | |
| SCHEMBL1022486 | 0.92 | ALOX5 (0.36) | ACHEBACE1ALOX5PTGS2GLS2 | |
| SCHEMBL6282240 | 0.89 | GPR84 (0.42) | ACHEBACE1ALOX5PTGS2GLS2 | |
| SCHEMBL3505646 | 0.86 | GPR84 (0.40) | ACHEBACE1ALOX5PTGS2GLS2 | |
| SCHEMBL1021705 | 0.83 | — | — | |
| SCHEMBL4869101 | 0.80 | MAPT (0.35) | ACHEBACE1ALOX5PTGS2GPR84 | |
| SCHEMBL4865720 | 0.80 | ALOX5 (0.34) | ACHEBACE1ALOX5PTGS2 | |
| SCHEMBL8636592 | 0.73 | ACHE (0.37) | ACHEBACE1ALOX5GPR84MPEG1 | |
| SCHEMBL6060419 | 0.73 | TDP1 (0.35) | — | |
| SCHEMBL9360177 | 0.73 | ACHE (0.37) | ACHEBACE1ALOX5GPR84MPEG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0110142-B1 | PROCESS FOR THE PREPARATION OF ALKYLATED CYCLOPENTENONES, AND ACETYLENIC ESTERS USEFUL AS STARTING COMPOUNDS IN SAID PREPARATION | FIRMENICH SA (CH) | 1986-12-30 | — | — | EP | claimed |
| US-4499297-A | CYCLIZATION AND REARRANGEMENT OF AN 1-ALKYNYL-2-ALKYL-2-PROPENYL ESTER USING A NOBLE METAL HALIDE-NITRILE CATALYST | FIRMENICH, SA (CH) | 1985-02-12 | — | — | US | claimed |
| EP-0110142-A2 | Process for the preparation of alkylated cyclopentenones, and acetylenic esters useful as starting compounds in said preparation | FIRMENICH SA (CH) | 1984-06-13 | — | — | EP | claimed |
| US-20080125310-A1 | Hydride reduction of alpha, beta-unsaturated carbonyl compounds using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-05-29 | — | — | US | disclosed |
| US-7323604-B2 | Hydride reduction of α,β-unsaturated carbonyl compounds using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-01-29 | — | — | US | disclosed |
| US-20060161024-A1 | Hydride reduction of alpha, beta-unsaturated carbonyl compounds using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-07-20 | — | — | US | disclosed |
| US-4970345-A | REARRANGEMENT, HYDROGENATION, DEHYDRATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-11-13 | — | — | US | disclosed |
| US-3953514-A | Process for preparing cyclopentenone derivatives | UBE INDUSTRIES, LTD. (JA) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060161024-A1 | Hydride reduction of alpha, beta-unsaturated carbonyl compounds using chiral organic catalysts | ECH1, CBR1, DHCR24 | ACHE 1633/4885BACE1 795/4885ALOX5 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.